logging in or signing up Menopausal Syndrome rka10 Download Post to : URL : Related Presentations : Let's Connect Share Add to Flag Embed Email Send to Blogs and Networks Add to Channel Copy embed code: Embed: Flash iPad Dynamic Copy Does not support media & animations Automatically changes to Flash or non-Flash embed WordPress Embed Customize Embed URL: Copy Thumbnail: Copy The presentation is successfully added In Your Favorites. Views: 721 Category: Entertainment License: All Rights Reserved Like it (0) Dislike it (0) Added: July 06, 2011 This Presentation is Public Favorites: 1 Presentation Description No description available. Comments Posting comment... Premium member Presentation Transcript Menopausal Syndrome : Menopausal Syndrome Introduction : Introduction Permanent cessation of menstruation due to loss of ovarian follicular function Diagnosed retrospectively after 12 months of amenorrhea Average age is 51 years Perimenopause : Perimenopause Introduction : Introduction Time period preceding menopause when fertility decreases, menstrual irregularities increase Onset of perimenopause precedes the final menses by 2 to 8 years Smoking accelerates the menopausal transition by 2 years Physiology : Physiology Ovarian mass and fertility decline sharply after the age of 35 years Depletion of primary follicles Rise in FSH levels due to Altered folliculogenesis Reduced inhibin secretion Physiology : Physiology Consistently high FSH and low Estradiol levels in Menopause Perimenopause – irregularly irregular hormone levels Physiology : Physiology Anovulatory cycles produce Hyperestrogenic / Hypoprogestagenic environment and increases the incidence of Endometrial Hyperplasia or Carcinoma Uterine polyps Leiomyoma Physiology : Physiology With transition into menopause Marked fall of Estradiol levels Relative preservation of estrone levels due to Peripheral aromatization of adrenal and ovarian androgens Increase in FSH levels more than those of Luteinizing Hormone Investigations : Investigations History General examination: BP, Weight, Breast, Hirsuitism Pelvic examination; Pap smear Blood sugar, lipid profile Mammography, pelvic ultrasound (Ovarian size, Endometrial Thickness) Bone Mineral Density Oestradiol level and FSH – to decide on need for HRT Diagnostic Tests : Diagnostic Tests Low FSH in the early follicular phase of the menstrual cycle is inconsistent with a diagnosis of perimenopause FSH and fertility < 20, 20 to 30 mIU/ml and 30 on day 3 of the cycle means Good, Fair or Poor chance of pregnancy Symptoms : Symptoms Menopausal transition causes Hot flushes Night sweats Irregular bleeding Vaginal dryness Sleep disturbances Symptoms : Symptoms Mood swings Depression Impaired memory or concentration Somatic symptoms Urinary incontinence Sexual dysfunction Treatment : Treatment Irregular or Heavy bleeding - Low dose combined oral contraceptives (20 µgm of Ethinyl Estradiol + 1 mg Norethindrone Acetate) daily for 21 days each month eliminates vasomotor symptoms and regularizes cycles Protects against ovarian cancer / endometrial cancers Increases bone density Contraceptive effect Contraindications : Contraindications Oral contraceptives Cigarette smoking Liver Disease Thromboembolism / Cardiovascular disease Breast Cancer Unexplained vaginal bleeding Treatment : Treatment Progestin only formulations 0.35 mg Norethindrone daily Medroxy progesterone injections (Dipoprovera 150 mg) IM every 3 months In people who smoke or have increased Cardiovascular risk Treatment : Treatment Non hormonal Strategies to reduce menstrual flow Non steroidal anti-inflammatory Mefenamic acid Initial dose of 500 mg at start of menses Then 250 mg QID for 2 to 3 days Endometrial Ablation Investigations : Investigations For menorrhagia rule out uterine disorders with Transvaginal ultrasound with saline enhancement for detecting Leiomyomata or polyps Endometrial aspiration for identifying Hyperplastic changes Transition : Transition Transition to Menopause 1 year absence of spontaneous menses indicates ovulation cessation Age of final menses among relatives is a reliable guide Hormone Therapy : Hormone Therapy Hormone therapy in Menopause and Post Menopausal cases The largest trial by Women’s Health Initiative (WHI) Hormone Therapy : Hormone Therapy Definite Benefits Definite improvement in symptoms of menopause Definite increase in bone mineral density and decrease in fracture risk in cases of Osteoporosis Hormone Therapy : Hormone Therapy Definite Risks In Endometrial Cancer, there is definite increase in risk with estrogen alone; no increase in risk with estrogen progestin In venous Thromboembolism, there is definite increase in risk In Breast Cancer, there is increase in risk with long-term use ( 5 years) of estrogen progestin In Gall bladder disease, there is definite increase in risk Hormone Therapy : Hormone Therapy Uncertain risks and Benefits Increased risk in Coronary Heart Disease, Stroke, Ovarian cancer Decreased risk in Colorectal Cancer, Diabetes Mellitus, Cognitive Dysfunction Definite Benefits : Definite Benefits Estrogen therapy is highly effective for controlling vasomotor and genitourinary symptoms Definite Benefits : Definite Benefits Alternative approaches Antidepressants (Venlafaxine 75 to 150 mg/dl) Gabapentin 300 to 900 mg/dl Clonidine 0.1 to 0.2 mg/dl Vitamin E – 400 to 800 IU/dl Soy-based products or other phytoestrogens Vaginal estrogen for Genitourinary symptoms Bone Density : Bone Density By reducing bone turnover and resorption rates, estrogen slows the aging related bone loss which is experienced by most postmenopausal women Estrogen Therapy : Estrogen Therapy Postmenopausal estrogen therapy with / without a progestogen, rapidly increases bone mineral density at Spine by 4 to 6% Hip by 2 to 3 % Fractures : Fractures 50 to 80% - lower risk of vertebral fracture 25 to 30% - lower risk of hip, wrist and other peripheral fractures Treatment : Treatment Bisphosphonates Alendronate 10 mg/day or 70 mg once per week Risedronate 5 mg/day or 35 once per week Ibandronate 2.5 mg/day or 150 mg once per week or 3 mg every 3 months IV Selective Estrogen Receptor Modulator (SERM) Ralofexine 60 mg/day It increases bone mass density & decrease fracture rates Treatment : Treatment Parathyroid Hormone Teriparatide 20 µgm / day (s/c) Increased physical activity Adequate Calcium (1000 to 1500 mg/day through diet) Vitamin D (400 to 800 IU/day) Definite Risks : Definite Risks Endometrial Cancer (With Estrogen alone) Venous Thromboembolism Breast Cancer (With Estrogen-Progestin) Gallbladder disease Endometrial Cancer (With Estrogen alone) : Endometrial Cancer (With Estrogen alone) Tripling of endometrial cancer risk among short term (1 to 5 years) users of unopposed estrogen Nearly ten fold risk among users (> 10 years) Venous Thromboembolism : Venous Thromboembolism Doubling of venous thromboembolism risk in postmenopausal women with estrogen use WHI indicate a two fold increase in risk of venous and pulmonary thromboembolism associated with estrogen-progestin One third increase in this risk with estrogen only therapy Breast Cancer (With Estrogen-Progestin) : Breast Cancer (With Estrogen-Progestin) Increased risk of breast cancer among estrogen users Short term use (< 5 years) of post menopausal HT did not appreciably elevate breast cancer incidence Long term use (> 5 years was associated with a 35% increase in risk Combined estrogen – progestin regimens appear to increase breast cancer risk more than estrogen alone In the Heart and Estrogen / Progestin Replacement Study, 4 years of combination therapy, 27% increase in breast cancer risk. Gallbladder Disease : Gallbladder Disease Two to three fold increased risk of gallstones or cholecystectomy among postmenopausal women taking oral estrogen WHI – Estrogen – Progestin 67% and Estrogen alone 93% (Greater risk) for cholecystectomy Transdermal hormonal therapy may not increase Probable or Uncertain Risks and Benefits : Probable or Uncertain Risks and Benefits Coronary Heart Disease / Stroke Colorectal Cancer Cognitive Decline and Dementia Ovarian Cancer and Other Disorders Coronary Heart Disease / Stroke : Coronary Heart Disease / Stroke Estrogen use leads to 35 - 50% reduction in CHD Exogenous estrogen lowers plasma low-density lipoprotein (LDL) cholesterol Raises high-density lipoprotein (HDL) cholesterol levels by 10 to 15% Coronary Heart Disease / Stroke : Administration of estrogen favourably affects Lipoprotein (a) levels LDL oxidation Endothelial vascular function Fibrinogen Plasminogen activator inhibitor - 1 Coronary Heart Disease / Stroke Coronary Heart Disease / Stroke : Administration of estrogen unfavourably affects Other biomarkers of cardiovascular risk Boosts triglyceride levels Promotes coagulation via Factor VII, Prothrombin fragments 1 & 2, and fibrinopeptide A elevations Raises levels of the inflammatory marker C-reactive protein Coronary Heart Disease / Stroke Coronary Heart Disease / Stroke : Coronary Heart Disease / Stroke Lower risk of CHD in women who choose to start Hormone therapy within 4 years of menopause than non users Estrogen / Combined Estrogen – Progestin in women with pre-existing cardiovascular disease has not confirmed the benefits Colorectal cancer : Colorectal cancer Hormone therapy reduces risks of colon and rectal cancer In WHI, Estrogen – Progestin 44% reduction in colorectal cancer No benefit with estrogen only Cognitive Decline and Dementia : Cognitive Decline and Dementia Post menopausal Hormone Therapy is associated with a 34% decreased risk of dementia (Meta-analysis) WHI – no benefit of estrogen or estrogen – progestin therapy on the progression of mild to moderate Alzheimer’s disease Ovarian Cancer and other disorders : Ovarian Cancer and other disorders Hormone therapy increases the risk of ovarian cancer Reduces the risk of Type 2 Diabetes Mellitus WHI supports these findings Post Menopausal Hormone Therapy : Post Menopausal Hormone Therapy Approach to the patient Potential side effects Vaginal bleeding Contraindications to Hormone Therapy Indications for Hormone Therapy : Indications for Hormone Therapy Moderate to severe menopausal symptoms Vasomotor Urogenital symptoms in the absence of vasomotor can be treated with vaginal estrogen Contraindications to Hormone Therapy : Contraindications to Hormone Therapy Unexplained vaginal bleeding Active liver disease Venous Thromboembolism History of endometrial / breast cancer History of CHD, stroke, TIA or DM Contraindications to Hormone Therapy : Relative Contraindications Hypertriglyceridemia (> 400 mg /dL) Active gallbladder disease Transdermal estrogen may be an option for cases of Relative Contraindication Contraindications to Hormone Therapy Contraindications to Hormone Therapy : A woman who suffers an acute coronary event or stroke while on Hormone Therapy should stop therapy immediately Contraindications to Hormone Therapy Short Term use of Hormone Therapy : < 5 years For relief of menopausal symptoms If contraindicated Antidepressants Gabapentin Clonidine Soy / black cohosh Genitourinary symptoms Intravaginal estrogen cream / device Short Term use of Hormone Therapy Long Term use of Hormone Therapy : Long Term use of Hormone Therapy 5 years (especially estrogen– progestogen) Reasonable candidates Persistent severe vasomotor symptoms Increased risk of Osteoporosis No personal / family history of breast cancer Long Term use of Hormone Therapy : Poor candidates are women with Elevated cardiovascular risk Increased risk of breast cancer Low risk of Osteoporosis Long Term use of Hormone Therapy Slide 53: Thank You You do not have the permission to view this presentation. In order to view it, please contact the author of the presentation.